13075_2016_948_MOESM1_ESM.docx (1.38 MB)
Additional file 1: Figure S1. of MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
journal contribution
posted on 2016-02-27, 05:00 authored by Kazuko Shiozawa, Takashi Yamane, Miki Murata, Ryosuke Yoshihara, Ken Tsumiyama, Shigeaki Imura, Shunichi ShiozawaAnnual changes in disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and European League Against Rheumatism (EULAR) response. Figure S2. Receiver operating characteristic (ROC) curve analysis showing that serum matrix metalloproteinase-3 (MMP-3) levels measured at the outset of methotrexate (MTX) monotherapy can predict radiographic evidence of non-progression in male (a) and female (b) patients, respectively. Table S1. Relationship between disease activity score (DAS) and van der Heijde modified total Sharp score year-progression (âTSS). (DOCX 1416 kb)